GSK officer acquires ADS under pension plan

Q: Who at GSK (GSK) was involved in the reported ADS transaction?

The transaction involved Diana Conrad, GSK’s Chief People Officer. She acquired American Depositary Shares under the company’s pension plan, as reported in the Form 6-K, and the deal took place on the New York Stock Exchange on 2 March 2026.

Q: What type of security did GSK (GSK) report being acquired?

GSK reported the acquisition of American Depositary Shares (ADS) with ISIN US37733W2044. These ADS represent GSK equity and were purchased under the GSK pension plan on the New York Stock Exchange at a price of $58.6439 per ADS.

Q: At what price and volume were GSK (GSK) ADS acquired in this transaction?

The reported transaction covered 11.569 ADS at a price of $58.6439 per ADS. This was a single acquisition under the GSK pension plan, executed on the New York Stock Exchange and disclosed as aggregated information not required due to being one transaction.

Q: When and where was the GSK (GSK) ADS transaction executed?

The ADS transaction was executed on 2026-03-02 on the New York Stock Exchange (XNYS). It involved the acquisition of American Depositary Shares by Chief People Officer Diana Conrad under the GSK pension plan, as detailed in the Form 6-K disclosure.

Q: How is the nature of GSK (GSK) Chief People Officer’s transaction described?

The transaction is described as an acquisition of ADS under the GSK pension plan. This indicates the shares were obtained through a company-related benefit arrangement rather than an open-market discretionary trade, and it was reported as a single transaction in the filing.

GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares under the GSK pension plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc reported that Chief People Officer Diana Conrad acquired American Depositary Shares under the GSK pension plan. The transaction involved 11.569 ADS at a price of $58.6439 per ADS, executed on 2026-03-02 on the New York Stock Exchange.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that Chief People Officer Diana Conrad acquired ADS under the GSK pension plan. The transaction involved 11.569 American Depositary Shares at a price of $58.6439 per ADS, carried out on the New York Stock Exchange on 2 March 2026.

Who at GSK (GSK) was involved in the reported ADS transaction?

The transaction involved Diana Conrad, GSK’s Chief People Officer. She acquired American Depositary Shares under the company’s pension plan, as reported in the Form 6-K, and the deal took place on the New York Stock Exchange on 2 March 2026.

What type of security did GSK (GSK) report being acquired?

GSK reported the acquisition of American Depositary Shares (ADS) with ISIN US37733W2044. These ADS represent GSK equity and were purchased under the GSK pension plan on the New York Stock Exchange at a price of $58.6439 per ADS.

At what price and volume were GSK (GSK) ADS acquired in this transaction?

The reported transaction covered 11.569 ADS at a price of $58.6439 per ADS. This was a single acquisition under the GSK pension plan, executed on the New York Stock Exchange and disclosed as aggregated information not required due to being one transaction.

When and where was the GSK (GSK) ADS transaction executed?

The ADS transaction was executed on 2026-03-02 on the New York Stock Exchange (XNYS). It involved the acquisition of American Depositary Shares by Chief People Officer Diana Conrad under the GSK pension plan, as detailed in the Form 6-K disclosure.

How is the nature of GSK (GSK) Chief People Officer’s transaction described?

The transaction is described as an acquisition of ADS under the GSK pension plan. This indicates the shares were obtained through a company-related benefit arrangement rather than an open-market discretionary trade, and it was reported as a single transaction in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/04/2026 - 11:48 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS under the GSK pension plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		$58.6439	11.569
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-03-02
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: March 04, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR